Global Dengue
Vaccines Market
Share, Global Trends,
Analysis, Research, Report,
Opportunities,
Segmentation and Forecast,
2016-2026
Future Market Insights
www.futuremarketinsights.com
[email protected]
Future Market Insights (FMI) is a premier provider of syndicated research reports, custom research reports, and consulting
services. We deliver a complete packaged solution, which combines current market intelligence, statistical anecdotes,
technology inputs, valuable growth insights, aerial view of the competitive framework, and future market trends.
We provide research services at a global as well as regional level; key regions include GCC, ASEAN, and BRIC.
Our offerings cover a broad spectrum of industries including Chemicals, Materials, Energy, Technology, Healthcare, and
Retail.
We have a global presence with delivery centers across India specializing in providing global research reports and country
research reports. FMI is headquartered out of London, U.K., with a state-of-the-art delivery center located in Pune, India.
We combine our knowledge and learning from every corner of the world to distill it to one thing – the perfect solution for
our client.
Research Capabilities
Sector Coverage








Customized Research
Syndicated Research
Investment Research
Social Media Research
Automotive and Transportation
Electronics, Semiconductor, and ICT
Retail and Consumer Products
Industrial Automation and Equipment
Customized
Research
Subscription Information
Syndicated
Research
For detailed subscription information please contact
Investment
Research
T: +44 (0) 20 7692 8790 | D: +44 20 3287 4268
Social Media
Research
Hari. T (Sr. Manager - Global Business Development)
Email: [email protected]




Chemicals & Materials
Food and Beverages
Services and Utilities
Energy, Mining, Oil, and Gas
Report
Description
Report Description
Dengue is a mosquito-born flavivirus disease and causes dengue fever characterized by
severe headache, skin rash, debilitating muscle, joint pain leaving a feverish feeling. The
dengue virus is also called as ‘breakbone fever’ due to the symptoms it causes. The
symptoms for dengue start appearing in the span of 3-14 days and can infect infants,
young children and adults. Dengue has emerged as one of the critical vector-borne
diseases especially in tropical and subtropical regions of the world. The first dengue
vaccine, Dengvaxia (CYD-TDV) developed by Sanofi Pasteur registered in Mexico in
December, 2015. CYD-TDV vaccine is a live recombinant tetravalent dengue vaccine
which was evaluated as a 3 dose series 0/6/12 month schedule in Phase III clinical
studies. There are around five other vaccine candidates under evaluation in clinical trials,
comprising other live-attenuated vaccines, as well as subunit, DNA and purified
inactivated vaccine candidates. Along with the developments in dengue vaccines
additional technological approaches, such as virus-vectored and VLP-based vaccines, are
held under evaluation in preclinical studies for further advancements.
The development for dengue vaccine had begun by 1929 but was delayed due to the
incomplete knowledge of the diseases. Sanofi Pasture first approved the vaccine for
dengue in 2015 and integrated dengue prevention reducing the mortality rate by almost
50%. WHO Strategic Advisory Group of Experts (SAGE) on Immunization reviewed CYDTDV in April 2016 and recommended countries to introduce the vaccine through its
Global dengue prevention and Control Strategy (2012-2020).
Report
Description
Report Description
Request for sample report: http://www.futuremarketinsights.com/reports/sample/repgb-1763
The drivers for dengue vaccine market include growing healthcare concerns, increase in
mortality rate because of dengue fever. And the challenges faced by the scientist in
developing this vaccines were majorly due to the complexity of the dengue virus,
expensive trials and time to develop them. After the introduction of Dengvaxia (CYDTDV), five additional candidates are I clinical trials. The prices for dengue vaccines are
much higher but due to government intervention the vaccine are sold on discounted
prices in most countries. In March 2016, Dengvaxia was licensed in Mexico, the
Philippines, Brazil and El Salvador for effective prevention against dengue from all four
serotypes which are mostly found in individuals of age 9-45 years living in endemic areas.
According to WHO (World Health Organization) dengue epidemics are being reported
every year from more than 100 endemic countries causing 50-100 million dengue
infections worldwide annually. In the years 2010, 2013 and 2015, nearly 2.4 million cases
of dengue had been reported indicating the sharp increase in the number. It was
estimated 500 000 people with severe dengue require hospitalization each year and from
them 2.5% of those affected die each year. The dengue vaccine is being produced in in
France in dedicated manufacturing site including a full-scale production capacity of 100
million of vaccine doses annually.
Report
Description
Report Description
In 2016, Philippines had registered to have the highest incidence of confirmed dengue
among the 10 endemic countries which had participated in clinical efficacy studies for the
vaccine. In April 2016, the first public dengue immunization program was started in the
Philippines. The major launch event which was hosted by the Department of Health
(DoH) of the Philippines, which lists the details about the country’s plan of vaccinating
about 1 million public school children and was shared with the international and national
press during the event. Where in February, Sanofi Pasteur’s dengue vaccine was firstly
made available for the private sector vaccination in the Philippines
Request for TOC: http://www.futuremarketinsights.com/toc/rep-gb-1763
In the history of global burden of diseases, dengue which bears about 70% of it had an
optimism after the first approval of the vaccine. Due to the developments in the recent
years, pharmaceutical companies have started making effort in developing dengue
vaccine and have registered their products for clinical trials. Companies such as
GlaxoSmithKline plc, Merck & Co., Inc. and Takeda Pharmaceutical Company Ltd. are each
at different stages in developing the vaccines for dengue.
Thank You!
To know more about us, please visit our website:
www.futuremarketinsights.com
For sales queries or new topics email us on:
[email protected]
Future Market Insights: 616 Corporate Way, Suite 2-9018,
Valley Cottage, NY 10989, United States
T: +1-347-918-3531 | D: +1-845-579-5705